Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $5.08 and traded as high as $5.38. Oramed Pharmaceuticals shares last traded at $5.38, with a volume of 102,162 shares traded.
Separately, ValuEngine downgraded shares of Oramed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, December 30th.
The business has a 50 day simple moving average of $5.15 and a 200 day simple moving average of $3.73. The stock has a market cap of $97.53 million, a PE ratio of -11.76 and a beta of 1.42.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Thursday, January 9th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.11. Oramed Pharmaceuticals had a negative return on equity of 38.51% and a negative net margin of 297.30%. The company had revenue of $0.67 million during the quarter. Sell-side analysts anticipate that Oramed Pharmaceuticals, Inc. will post -0.98 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its holdings in Oramed Pharmaceuticals by 50.5% in the second quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock worth $568,000 after buying an additional 53,043 shares during the last quarter. Jane Street Group LLC bought a new position in Oramed Pharmaceuticals during the second quarter valued at approximately $155,000. Tower Research Capital LLC TRC raised its position in Oramed Pharmaceuticals by 1,137.7% during the third quarter. Tower Research Capital LLC TRC now owns 18,491 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 16,997 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Oramed Pharmaceuticals in the third quarter valued at approximately $50,000. 4.29% of the stock is owned by institutional investors and hedge funds.
Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
See Also: Straddles
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.